Of note, combined ERK and CDK8/19 inhibition demonstrated no short-term synergy in any cell line (Fig. 2g, top), and CDK8/19 inhibition alone had a negligible effect on long-term basal growth (Supplementary Fig. 2g), positioning this combination as a promising strategy for preventing long-term acquired resistance in KRAS-mutant cancers. Here, KRAS is linked to cancer.